Sixth Street Chief Science Adviser and Nobel laureate Jennifer Doudna, co-founder of the CRISPR genome editing technology 10 years ago, and Sixth Street Vice Chairman and Partner R. Martin Chavez join Emily Chang to discuss the future of CRISPR and its potential for commercialization.
-
- 1
Francisco Gimeno - BC Analyst Biotech is advancing rapidly, and at its peak is CRISPR tech. It has a lot of exciting possibilities and already some success. The future of all this will depend not just on the technological side, but also on how we do handle the ethical issues which will undoubtedly arise from its use, and its long term safety and security (weird mutations anyone?). Meanwhile, another example on how the concept of being human is changing in the new cultural and technological paradigm.